Project Grant R01DK146472
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded $249,000 to The University of Texas Southwestern Medical Center (UT Southwestern) on September 9, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to support novel genetic research on celiac disease (CED). The project, which extends through August 31, 2027, delivers comprehensive genomic research services designed to identify...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded The Trustees of Columbia University in the City of New York a $587,470 Project Grant on March 16, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award supports research to elucidate the role of a long noncoding RNA designated LNC15 in inflammatory bowel disease (IBD) pathogenesis. The research deliverables include...
- Federal Grant Award Summary Columbia University's Health Sciences Division received a $123,375 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded February 15, 2026, with a completion date of January 31, 2028. The award funds basic biomedical research investigating epithelial cell biology in preclinical mouse models of early-onset eosinophilic...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded The Trustees of Columbia University in the City of New York $784,280 through the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct research on post-transcriptional modifications in esophageal basal cells. The award, effective September 15, 2025, with completion targeted for July 31, 2030, supports investigator-initiated basic...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $196,460 Project Grant to The Trustees of Columbia University in the City of New York (Health Sciences Division) on June 23, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award supports investigator-initiated biomedical research designed to improve understanding of disease mechanisms and develop improved prevention,...
- Grant Award Summary The University of Colorado-Denver received a $234,000 Project Grant awarded on September 15, 2025, from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). This two-year award, concluding September 14, 2027, supports investigator-initiated biomedical research aimed at elucidating the role of AIOLOS in T cell-mediated pathogenesis of inflammatory bowel disease...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded The Trustees of Columbia University in the City of New York a Project Grant of $231,270 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on September 15, 2025, with completion targeted for August 31, 2027. This award supports large-scale exome-wide rare variant association studies designed to advance chronic kidney disease (CKD) risk...
- Federal Project Grant Award Summary Icahn School of Medicine at Mount Sinai received a $1,291,234 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) effective July 1, 2025, with completion targeted for April 30, 2030. The award supports basic biomedical research investigating hematopoietic stem cell (HSC) dysfunction as a mechanism underlying refractory...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Columbia University's Health Sciences Division a $838,425 Project Grant effective May 1, 2026, through March 31, 2031, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research project focuses on nutrient sensing in pro-opiomelanocortin (POMC) neurons and the mechanisms by which glucose and lactate regulate these hypothalamic neurons to...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Scripps Research Institute a $801,662 Project Grant effective August 15, 2025, through June 30, 2029, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research project investigates the initiation of anti-islet autoimmunity in Type 1 Diabetes (T1D), a CD4 T cell-mediated autoimmune disease, with particular focus on understanding the role...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded The Trustees of Columbia University in the City of New York a Project Grant of $821,018 (awarded May 1, 2026; completion date February 28, 2031) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research initiative focuses on elucidating the mechanisms of celiac disease (CD) pathogenesis, specifically investigating how gluten-specific CD4+ T cells and cytotoxic CD8+ and gamma-delta T cells contribute to small intestinal tissue damage. The project deliverables include mechanistic studies dissecting how gluten modulates natural T cell populations in CD patients and identifying tissue-derived factors that unleash the cytotoxic capacity of intraepithelial lymphocytes, with the ultimate goal of advancing understanding of autoimmune disease mechanisms applicable beyond celiac disease. This research represents a significant opportunity to advance therapeutic interventions for celiac disease, one of the most prevalent autoimmune disorders worldwide with currently limited treatment options beyond a lifelong gluten-free diet. The project leverages the unique advantage of celiac disease as a model autoimmune condition where the triggering antigen—dietary gluten—is known and controllable, enabling rigorous investigation of human autoimmunity pathways. Conducted at Columbia University's Health Sciences Division in New York, the research findings may inform development of novel treatment strategies and provide insights applicable to understanding broader mechanisms of autoimmune-mediated tissue destruction.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $821.0k | 4/28/26 |